Boston Scientific Unveils Early Taxus Sales Data; Cordis Looks Long-Term
This article was originally published in The Gray Sheet
Executive Summary
Taxus appears to have bolted out of the gate, based on Boston Scientific's March 22 report that the paclitaxel-eluting stent has achieved about 80% of its low-end sales goal in less than half the time predicted
You may also be interested in...
St. Jude’s Epic Year Wins Over Investors; MDDI Index Up 15% In 2004
St. Jude Medical's entry into the cardiac resynchronization therapy ICD market and expanded atrial fibrillation business helped capture the attention of Wall Street and potential suitors in 2004 as its stock jumped 37% for the year
St. Jude’s Epic Year Wins Over Investors; MDDI Index Up 15% In 2004
St. Jude Medical's entry into the cardiac resynchronization therapy ICD market and expanded atrial fibrillation business helped capture the attention of Wall Street and potential suitors in 2004 as its stock jumped 37% for the year
Cordis Recruits Guidant To Block Taxus, Develop Combined Delivery System
Johnson & Johnson/Cordis is betting that its drug-eluting stent marketing alliance with Guidant will allow it to match Boston Scientific's sales presence in U.S. cath labs